Syndicate content

Genome Sequencing Found Feasible & Informative for Pediatric Cancer Treatment; Recommendations Reported at ASHG 2018 Annual Meeting; Work Is Part of St. Jude’s “Genomes for Kids” Study

Comprehensive genetic testing of tumors and non-cancerous tissue from pediatric cancer patients is a feasible and clinically useful approach that can guide patient care, according to findings presented on October 17 at the American Society of Human Genetics (ASHG) 2018 Annual Meeting in San Diego, California (October 16-20). The ASHG reports a record attendance of 8,500 for this year's meeting. Presenting author Scott Newman, PhD; Jinghui Zhang, PhD; and Kim Nichols (photo), MD, along with an interdisciplinary team at St. Jude Children’s Research Hospital, studied 253 pediatric oncology patients with a variety of cancers. In 79 percent of cases, there was at least one finding that could help guide care by providing a diagnosis, revealing patient-specific risks, or identifying drug targets. The researchers conducted whole genome sequencing (WGS), whole exome sequencing (WES), and RNA sequencing of the patients’ tumors, as well as WGS and WES of non-cancerous tissue from the same patient. WGS involves sequencing the patient’s complete genome, while WES involves sequencing those portions that are transcribed into mRNA, most of which codes for proteins. This work was part of the “Genomes for Kids” study (G4K), a large effort to understand how best to use genetic data for pediatric cancer diagnosis and treatment. Differing from other studies that require a specific diagnosis to participate, this study had no prerequisite beyond the presence of adequate tumor tissue for testing. “To my knowledge, this is the first study to offer comprehensive sequencing prospectively for all new patients with adequate samples," said Dr. Nichols. She also noted that the diversity of cancers that were tested helped to verify the relationships between genetic variants and disease. Dr. Zhang and her colleagues developed software pipelines and analysis methods to identify the most clinically relevant variants. Most of their findings were structural rearrangements of DNA within or between chromosomes, and thus would have been challenging to detect (or not detected at all) using other, less comprehensive methods. With an eye to implementation, the researchers also showed that this comprehensive testing would not overburden the analysis process, and that information could be provided within about 40 days, a time frame short enough to be of clinical value.

Dr. Newman said that their work started out as a feasibility study, but it became clear that, in many patients, the results were applicable to treatment decisions. Looking forward, the researchers hope their findings will lead to the adoption of WGS for all pediatric cancer patients.

“With results available in a clinically relevant time frame, and pricing becoming increasingly comparable to the radiology and pathology tests, WGS is becoming more accessible to pediatric oncology patients,” said Dr. Newman.

St. Jude has compiled the information from G4K into a publicly accessible online database (https://www.stjude.cloud/), encouraging global collaboration and further analysis of its data.

The researchers have continued to perform sequencing on current patients, and since the original study ended, have successfully used this method on roughly 300 additional patients.

The team plans to continue studying sequencing methods, in hopes of producing clinically applicable data in an even more timely manner.

The title of the presentation abstract is “Sequencing of Whole Genome, Exome, and Transcriptome for Pediatric Precision Oncology: Somatic Variants and Actionable Findings from 253 Patients Enrolled in the Genomes for Kids Study.”

[Press release] [Genomes for Kids brochure] [St. Jude Cloud Data Sharing Resource “Advancing Cures Through Data and Discovery”] [ASHG Annual Meeting 2018]